代谢性合并症与药物性肝损伤的发生、严重程度及其风险
Metabolic Comorbidities and Risk of Development and Severity of Drug-Induced Liver Injury.
机构信息
Department of Hepatology, The First Hospital of Jilin University, Jilin University, No. 71 Xinmin Street, Changchun 130021, China.
出版信息
Biomed Res Int. 2019 Aug 18;2019:8764093. doi: 10.1155/2019/8764093. eCollection 2019.
The incidence and rates of diagnosis of drug-induced liver injury (DILI) have been increasing in recent years as findings from basic research and the examination of clinical databases reveal information about the clinical course, etiology, and prognosis of this complex disease. The prevalence of metabolic comorbidities (e.g., diabetes mellitus, fatty liver, obesity, and metabolic syndrome (MetS)) has been increasing during the same period. The results of preclinical and clinical research studies indicate that characteristics of metabolic comorbidities are also factors that affect DILI phenotype and progression. The objective of this review is to present the evidence for DILI and hepatotoxicity mechanisms, incidence, and outcomes in patients with MetS and nonalcoholic fatty liver disease. Moreover, we also summarize the relationships between drugs used to treat metabolic comorbidities and DILI.
近年来，随着基础研究和临床数据库检查结果揭示了这种复杂疾病的临床过程、病因和预后信息，药物性肝损伤（DILI）的发病率和诊断率一直在上升。同期，代谢性合并症（如糖尿病、脂肪肝、肥胖和代谢综合征（MetS））的患病率也在上升。临床前和临床研究结果表明，代谢性合并症的特征也是影响 DILI 表型和进展的因素。本综述的目的是介绍代谢综合征和非酒精性脂肪性肝病患者的 DILI 和肝毒性机制、发病率和转归的证据。此外，我们还总结了用于治疗代谢性合并症的药物与 DILI 之间的关系。
Zotero 插件